Abstract
Introduction::
Head and neck cancer is one of the most common tumors worldwide. However, drug resistance in its treatment has become a major factor limiting the efficacy. This study aims to comprehensively understand the current status of research in this field.
Methods::
The study analyzes papers related to therapeutic resistance in head and neck cancer published between 2000 and 2023 in the Web of Science Core Collection To achieve the research objectives, we searched the WoSCC for research and review papers on therapeutic resistance in head and neck cancer from 2000 to 2023, screened the English literature, and analyzed the research hotspots, academic collaborations, and trends in detail using tools such as Citespace, SCImago Graphica, and VOS viewer.
Results::
This study summarizes 787 head and neck cancer treatment resistance publications from WoSCC. The analysis showed that China and the United States are the major contributors in this field, and Grandis Jennifer R and Yang Jai-Sing are the key scholars. Keyword analysis showed that “cisplatin resistance” is a continuing focus of attention, while “Metastasis” and “Ferroptosis” may be emerging research hotspots. Literature clustering analysis pointed out that “Ferroptosis”, “Immunotherapy” and “ERK signaling” were the recent hotspots that received extensive attention and citations. Finally, we discuss the current status and challenges in drug-resistant therapies for head and neck cancer.
Conclusion::
This study is the first comprehensive bibliometric analysis of drug resistance in head and neck cancer. Reveals current trends and helps researchers grasp cutting-edge hotspots in the field.
1 Introduction
Head and neck cancer is a common malignant tumor worldwide. It covers a range of tumors in the oral cavity, nasal cavity, pharynx, larynx and neck (Tumban, 2019). The most common subtype of the disease is squamous cell carcinoma, while other types such as adenocarcinoma and small cell carcinoma are also included (Jumaniyazova et al., 2022). Drug-adjuvant therapies such as chemotherapy and immunotherapy play a key role in the treatment of head and neck cancer, improving surgical outcomes and reducing recurrence risk. (Harrington et al., 2023; Liu et al., 2024a). However, drug resistance during treatment limits long-term efficacy. In particular, drug resistance is driven by complex changes in cell signaling pathways (Jha et al., 2023; Trocchianesi et al., 2023), as well as the tumor microenvironment (; Qiao et al., 2023; Zhang et al., 2023). Therefore, an in-depth understanding and study of the molecular basis of drug resistance is essential for the development of more effective therapeutic strategies. Future studies should explore new drug combinations, targeted therapies, and individualized resistance prevention strategies. This will likely enable them to overcome drug resistance challenges in head and neck cancer treatment.
As technology advances, head and neck cancer treatment has seen an array of new drug treatment options, including some high-profile new drugs. First, anti-PD-1/PD-L1 immune checkpoint inhibitors, such as nivolumab (Marco et al., 2022) and pembrolizumab (Yuan et al., 2023), have made remarkable progress in head and neck cancer treatment in recent years (; Maroun and Mandal, 2021). These drugs have demonstrated excellent efficacy in some patients by activating the immune system and enhancing the body’s anti-tumor defense response. However, different individuals have different immune statuses, leading to variable therapeutic effects of these drugs. Secondly, targeted therapy has also become a major direction in head and neck cancer treatment (Stabile et al., 2013). For example, epidermal growth factor receptor (EGFR) inhibitors, such as cetuximab, inhibit tumor cell growth and division by interfering with the EGFR signaling pathway (Ratushny et al., 2009). Although these drugs have shown high efficacy in some patients, they are susceptible to drug resistance in long-term treatment, limiting their clinical application (; ; ). Finally, some herbal ingredients, such as baicalein in Scutellaria baicalensis, have antitumor activity (Tang and Dong, 2023). It has potential efficacy against drug-resistant head and neck cancer by inhibiting cancer cell proliferation and promoting apoptosis (Guo et al., 2019; Gao et al., 2020). In addition, artemisinin (Li, 2021) and its derivatives are complementary in traditional Chinese medicine (Roh et al., 2017). Studies have shown that they can regulate tumor cell signaling through multiple pathways and inhibit drug resistance in head and neck cancer. In general, head and neck cancer is treated with a variety of drugs, including immune checkpoint inhibitors, targeted therapies, and herbal treatments. However, differences in individual immune status and drug resistance due to long-term use are the main challenges to unstable therapeutic effects. Therefore, an in-depth study of drug resistance mechanisms in head and neck cancer is essential to optimize therapeutic strategies, overcome drug resistance, and promote innovative drug treatment options.
Bibliometrics is a method of assessing academic literature using mathematical and statistical methods (Wu et al., 2022). This approach allows us to analyze trends in a given field comprehensively. It also allows us to explore the contributions made by individuals from different institutions and countries. Medical fields have widely used bibliometrics as a research method in recent years (; Han et al., 2023). This paper is the first study to systematically analyze therapeutic drug resistance in head and neck cancer using bibliometric methods. We comprehensively applied bibliometric methods to analyze in-depth research advances in drug resistance in head and neck cancer, covering January 2000 to December 2023. This study is organized along six dimensions: 1) annual publication output and citation trends; 2) collaborative networks between countries and institutions; 3) author collaborative networks and contributions; 4) keyword co-occurrence and cluster analysis; 5) citation and cluster analysis of the literature; and 6) journal impact analysis. Combining the results of these analyses, we explore the current status and future direction of drug resistance research in head and neck cancer. At the same time, we also discuss the applications and challenges in this field. We aim to provide future researchers with novel perspectives and methods for drug resistance research in head and neck cancer.
2 Materials and methods
2.1 Data collection
The Web of Science Core Collection (WoSCC) is a comprehensive scholarly treasure trove covering more than 190 subject areas worldwide. The database is widely recognized as an outstanding resource for bibliometric research in a variety of disciplines, providing superior literature retrieval and citation analysis services (Han et al., 2023).
2.2 Bibliometric key terms
2.2.1 Analysis of influential authors
H-index is a measure of scholarly output and impact, indicating that H papers published by an author have been cited at least H times (Hirsch, 2005; Harzing, 2016). G-index emphasizes papers with more evenly distributed citations on the basis of H-index (), and M-index is an improvement of H-index by considering the number of years of academic experience (von Bohlen Und Halbach, 2011). The combination of publication volume, H-index, G-index and M-index can be used to more comprehensively evaluate scholars’ academic contribution and influence.
2.2.2 keywords and literature cluster analysis
In this study of keyword and literature co-citation clustering, the silhouette parameter is used to assess literature clustering quality (Rousseeuw, 1987). It has a value between −1 and 1, with closer to one indicating better clustering and closer to −1 indicating worse clustering. This parameter helps the researcher determine the separation and closeness of the literature points in the clusters.
In addition, LSI (Latent Semantic Indexing) and LLR (Log-Likelihood Ratio) are both algorithms applied for literature clustering. LSI uses Singular Value Decomposition (SVD) for dimensionality reduction to reduce the number of features and through semantic relatedness to map the literature in a low-dimensional space (). LLR uses a log-likelihood ratio test to find groups of significantly related literature by comparing lexical distributions among the literature (Glover and Dixon, 2004). Finally, the combined LSI and LLR algorithms for literature clustering analysis consider semantic and lexical relatedness. They improve a deeper understanding of literature sets’ multilevel structure.
2.3 Bibliometric visualization software
The study used bibliometric analysis and visualization software, including R 4.3.0, BiblioMetrix, Citespace, VOSviewer, SCImago Graphica, and the online tool MapEquation.
2.3.1 R 4.3.0
Based on R version 4.3.0, we conducted a comprehensive analysis of the literature related to drug resistance in head and neck cancer through the Bibliometric package (). First, by extracting and analyzing the annual keyword frequency and cumulative frequency, we revealed the hot areas of drug resistance research in head and neck cancer. Second, scholars with significant influence in this subject area were identified through detailed analysis of author contributions. Finally, we evaluated the impact of journals using Bradford’s Law to identify journals with significant status in head and neck cancer drug resistance research (Yatsko, 2012). This comprehensive scholarly analysis provides insights into key topics, journal quality, and scholarly contributions to head and neck cancer drug resistance research. This provides valuable research insights for the academic community.
2.3.2 Citespace advanced (v6.2.R2 and v6.2.R4)
Citespace is software for visualization and econometric analysis of scientific literature. It is mainly used to reveal key themes, author collaboration networks and research dynamics in the academic field (). This study reveals academic structure and research hotspots in the field by constructing author collaboration networks, keyword co-occurrence analysis and citation clustering. It can help researchers track author collaborations, discover research frontiers, and visualize literature citation networks. This helps to gain a deeper understanding of the whole picture of drug resistance mechanism research in head and neck cancer, and provides insights into the development of more effective therapeutic strategies.
2.3.3 VOSviewer and SCImago graphica
VOSviewer software plays a key role in head and neck cancer drug resistance bibliometric analysis in synergy with SCImago Graphica software. With VOSviewer, researchers can conduct collaborative network analyses of countries and institutions (Perianes-Rodriguez et al., 2016; Measuring Scholarly Impact: Methods and Practice | SpringerLink, 2024). This will reveal patterns of collaboration among different countries and institutions involved in head and neck cancer drug resistance research. In addition, VOSviewer combined with SCImago Graphica’s visual clustering analysis enables researchers to gain a deeper understanding of the organizational structure, research themes, and institutional groups in the research field. This helps to identify potential research trends, strengthen international collaborations, and provide comprehensive collaborative insights into scientific research in the field of drug resistance in head and neck cancer. The combination of the two provides researchers with a powerful tool to facilitate international collaborations and advance the research field.
2.3.4 MapEquation
By exporting the head and neck cancer drug resistance literature through Citespace and combining it with the online tool MapEquation (https://www.mapequation.org/apps/AlluvialGenerator.html), we present five consistently influential papers in a shock flow diagram (). This comprehensive analysis covers the core literature in the citation network and reveals its continued impact on the field’s development. MapEquation efficiently displays the citation flow of the literature in an impact flow diagram. This highlights the citation relationships between the literature and its contribution to the academic field. This approach provides a clear and comprehensive visualization for a deeper understanding of the literature. It has sustained impact in the field of drug resistance in head and neck cancer, providing valuable visual insights for academic research.
2.4 Statistical data analysis
This study used R (v4.3.0) to perform descriptive statistics and visualization. The fitted model for the trend analysis of the number of articles is the formula = y ∼ poly (x, 2). The fitted curve is a quadratic polynomial model based on the year x) and the number of publications y). The trend of the number of publications and the yearly citation trend are visualized in this study using the ggplot2 package.
3 Results
Figure 1 describes our elaborate retrieval method. By performing a title search (TI) in the WoSCC database, we successfully obtained 1020 original articles. Subsequently, 786 articles were finalized by filtering them according to year of publication (2000.01-2023.12), type of publication (articles and reviews), and language (English). We then exported these retrieved documents in plain text form and used the downloaded bibliographic records for bibliometric analysis.
FIGURE 1
3.1 Annual publication and citation trends
We used line graphs to present in detail the trend of growth in the number of papers and the trend of annual citation frequency in the field of head and neck cancer drug resistance research in the WoSCC database for the period from 2000 to 2023. In the overall study, we used R to fit a nonlinear model. This reveals the macro-trend that academic publications in this field are on the rise. In addition, we analyze this trend in depth by phase. Figure 2A shows a relatively flat growth trend in paper numbers between 2000 and 2010. Between 2011 and 2022, however, the number of papers in this field increased significantly. Taken together, our analysis reveals that drug resistance research in head and neck cancer has flourished, especially in recent years. This provides valuable insights into academic medicine.
FIGURE 2
In addition, we analyzed annual citation trends. As shown in Figure 2B, the trend can be divided into three parts: fluctuating (2000-2008), stable (2009-2017), and decreasing year by year (2018-2023). Combined with the trend of publications, we come up with five reasons: 1) Low-quality research: the increased number of publications may originate from low-quality or insufficiently influential research, which fails to attract other scholars’ attention and citations. Fragmentation of the field: As the number of publications increases, research may become more fragmented rather than concentrated on a few high-impact papers, which may lead to a decline in overall citations. 3) Citation lag: It may take time for citations to reflect the impact of research, and if the latest literature has not yet been fully cited, a decline in citations may be observed initially. 4) Changes in research direction: Changes in research direction within the field may cause a decline in citations. Citations may decrease if the proposed direction is not widely recognized or does not attract enough interest from the academic community.
In summary, head and neck cancer drug resistance research has shown significant growth between 2000 and 2023, especially explosive growth in recent years. The annual citation trend undergoes three phases of fluctuation, stabilization, and gradual decrease. This may be influenced by factors such as low-quality studies, field fragmentation, citation lag, changes in research direction, and potential data insufficiency or short-term fluctuations. These findings provide deep insights into the current state and trends of the field domain.
3.2 Analysis of national publications and institutional cooperation
The analysis of national publications and citation frequency provides a powerful tool for understanding the scientific ecosystem, international partnerships, and assessing a country’s position and influence in the field of head and neck cancer drug resistance research. Supplementary Table S1 analyzes national publication volume and citation frequency. Figure 3A shows that China, the United States, and Japan are in the top three countries in terms of national publications. In addition, China, the United States, and South Korea are in the top three countries in terms of standardized citations. These figures may reflect the overall research strength and activity of China, the U.S., and Japan in this field. In addition, the citation performance hints at these countries’ academic influence. South Korea’s performance in citation frequency compared with Japan may imply that its research in the field or direction of head and neck cancer drug resistance research has relatively higher academic value.
FIGURE 3
In addition, we analysed the collaborative connections between countries and institutions in drug resistance research in head and neck cancer. This was done to reveal the current status of international academic exchanges in this field. First, in Figure 3B, the strength of collaborative connections between countries is categorized into three clusters, among which the strength of collaboration between China and the United States is high and in the same category. Second, the United States acts as a key cooperation bridge between these three clusters. In addition, Figure 3C shows that Chinese medical universities lead the number of publications in this research area. Finally, Texas M. D. Anderson Cancer Research Center, on the other hand, acts as a link between these three clusters. It provides key support for drug resistance research in head and neck cancer.
3.3 Author contributions and cluster analysis
In the field of drug resistance research in head and neck cancer, an in-depth analysis of the authors’ contributions is intended to provide a better understanding of the dynamics of scientific research in the field, especially those researchers who have achieved remarkable results in overcoming therapeutic resistance.
Figure 4A visualizes the top 10 authors in terms of posts and highlights Citespace software users. Among the top 10 authors in terms of posts, Grandis Jennifer R and Yang Jai-Sing are at the top of the list with 13 posts each. In addition, the authors highlighted in red, Osmak Maja, Kim Eun Hye, Roh Jong-Lyel, and Lu Chi-Cheng, excelled in citations and were the most popular authors in the TOP4. Meanwhile, in Supplementary Figure S1, we present a timeline plot of the citation prominence of these four authors. Among them, Kim Eun Hye has the highest citation burst intensity of 4.32, lasting from 2016 to 2018.
FIGURE 4
In order to gain a deeper understanding of the research direction of authors in the field of head and neck cancer drug resistance research, we used LLR cluster analysis to obtain 46 clusters, in which the clusters from #0 to #46 were arranged in decreasing order of the number of authors. Meanwhile, analyzing the authors in combination with the TOP10 authors, we found that these authors were covered in 5 clusters. In Figure 4B, we show that authors with TOP10 publication volume were clustered into “#0 cetuximab”, “#4 osteopontin overexpression”, “#10 apoptosis”, “#29 cellular accumulation”, and “#34 pi3k inhibitor” in these five taxa. Therefore, through the analysis, we learned that these five taxa represent the research directions of TOP10 posting authors in the field of head and neck cancer drug resistance research.
In addition, we counted the publication volume, H-index, G-index and M-index of the TOP10 authors in this field in Supplementary Tables S2–S5, and further evaluated their scholarly influence and contribution to the field of head and neck cancer drug resistance research. First, in Figure 4C, we take the intersection of the authors of the TOP 10 of the above four indices using a Wayne diagram. This will enable us to obtain nine authors. Second, Figure 4D shows the annual publication volume of these nine authors. These nine authors have significantly contributed to the progress and development of head and neck cancer drug resistance research. They have done this with their excellent research output, high academic impact, and wide number of citations. Finally, Table 1 shows the institutions, publication volume, H-index, G-index, M-index, and total citation frequency of these nine authors. Their research results are of significant significance in guiding academic development and clinical practice of drug resistance research in head and neck cancer.
TABLE 1
| Rank | Authors | Institution | Counts | H_index | G_index | M_index | TC |
|---|---|---|---|---|---|---|---|
| 1 | Yang Jai-Sing | China Medical University (Taichung) | 13 | 12 | 13 | 1.091 | 583 |
| 2 | Grandis Jennifer R | University of California | 13 | 10 | 13 | 0.556 | 731 |
| 3 | Lu Chi-Cheng | National Taiwan University of Sport | 10 | 10 | 10 | 0.909 | 490 |
| 4 | Roh Jong-Lyel | CHA University School of Medicine | 11 | 10 | 11 | 0.833 | 1218 |
| 5 | Kim Eun Hye | University of Ulsan College of Medicine | 9 | 9 | 9 | 1.125 | 1159 |
| 6 | Li Wei | Weill Cornell Medicine | 12 | 8 | 12 | 0.571 | 168 |
| 7 | Shin Daiha | Korea Basic Science Institute | 8 | 8 | 8 | 1 | 1140 |
| 8 | Nakayama Hideki | Kumamoto University | 7 | 7 | 7 | 0.538 | 250 |
| 9 | Yoshida Ryoji | Kumamoto University | 7 | 7 | 7 | 0.538 | 250 |
The nine influential authors: Institution, counts, H/G/M index, and total citations.
3.4 Keyword co-occurrence and cluster analysis
Keyword co-occurrence analysis of drug resistance studies in head and neck cancer can reveal the interrelationships between keywords in head and neck cancer drug resistance studies, which helps to identify research hotspots and potential association mechanisms. We performed statistics and visualization of author keywords with VOSViewer. Figure 5A shows the keyword heat map, with darker colors representing higher keyword frequencies. In order to gain a deeper understanding of the hotspots and trends in drug resistance research in head and neck cancer, we categorized the keywords for frequency analysis. First, in Table 2, we categorized the keywords into 3 types of treatment methods, drug-resistant types, and research topics, and counted the frequency of TOP10 keywords in these three categories. In head and neck cancer drug-resistant treatment methods, cisplatin, cetuximab and paclitaxel keywords were Top 3. Cisplatin-resistant, anti-radiation and multi-resistant keywords were Top 3 in the drug-resistant group, and apoptosis, autophagy, EMT, EGFR and Cancer stem cell keywords were Top 3 in the research theme group. These high-frequency keywords reflect ongoing research hotspots. Secondly, we supplemented the statistics of keyword frequency in Supplementary Tables S6, S7 for therapeutic approach and research topic groups. Among them, drugs such as tetrandrine, temsirolimus, and triptolide in the drug therapeutics group potentially increase the sensitivity of anti-head and neck cancer drugs. And keywords such as extracellular vesicles, tumor microenvironment, and ferroptosis in the research topic group may reflect potential research hotspots in this field.
FIGURE 5
TABLE 2
| Rank | Treatment approaches | Counts | Drug resilience | Counts | Study themes | Counts |
|---|---|---|---|---|---|---|
| 1 | cisplatin | 63 | cisplatin resistance | 50 | apoptosis | 68 |
| 2 | cetuximab | 26 | radiation resistance | 38 | autophagy | 26 |
| 3 | paclitaxel | 19 | multiple drug resistance | 22 | EMT | 22 |
| 4 | 5-fluorouracil | 14 | insulin resistance | 12 | EGFR | 22 |
| 5 | immunotherapy | 9 | paclitaxel resistance | 9 | cancer stem cells | 22 |
| 6 | doxorubicin | 8 | cetuximab resistance | 4 | AKT | 19 |
| 7 | vemurafenib | 8 | resistance to thyroid hormone | 4 | metastasis | 17 |
| 8 | lenvatinib | 7 | erlotinib resistance | 2 | microRNA | 16 |
| 9 | sorafenib | 7 | immunotherapy resistance | 2 | p53 | 15 |
| 10 | resveratrol | 4 | 5-fu resistance | 2 | prognosis | 14 |
Top 10 treatment approaches, drug resilience, and study themes keyword frequency.
Keyword clustering analysis, on the other hand, groups high-value keywords. This provides researchers with a systematic understanding of the drug resistance mechanism of head and neck cancer and a direction for in-depth exploration. We used Citespace software for LLR and LSI cluster analysis and keyword visualization. We set the clustering parameter to TOP N = 30/40/50, and obtained 16, 15, and 16 clusters, respectively (Figure 5B, Supplementary Figures S2, S3). Figure 5B shows that the TOP N = 30 visualization result contains 16 keyword clusters. The number of keywords in the clusters decreases in the direction of the arrows. In addition, we analyze the same clusters using different clustering algorithms. This is to determine the research direction of the #2, #5, #7, #8, #11, and #13 clusters. LSI clustering is shown in red font and LLR clustering is shown in black font in Figure 5C. #2 and #5 demonstrate multi-resistance versus radiotherapy sensitivity in nasopharyngeal cancer. #7, on the other hand, indicates that RT-PCR is a commonly used tool in drug resistance studies. #8 shows that coenzyme Q-related genes are associated with drug resistance. #11 reflects the relationship between recovery training and survival quality. Finally, #13 reflects the potential value of peptide vaccines as immunotherapeutic tools in anti-head and neck cancer resistance studies.
Further, we are interested in revealing the current research focus, research trends and innovative directions in drug resistance in head and neck cancer. We will do this by visualizing the annual keyword frequency heatmap based on keyword set theory and topic network construction. Figure 5D heatmap presents the normalized frequency of authors’ keywords during 2000–2023, with annual keyword frequency on the left and cumulative annual keyword frequency on the right. In terms of drug therapy, paclitaxel, immunotherapy, cisplatin resistance and cetuximab constitute the focus of drug resistance research in head and neck cancer. In terms of thematic research, “MicroRNA”, “Metastasis”, The keywords “Ferroptosis” and “AKT”, highlighted in blue, have become an emerging focus in the field of drug resistance research in head and neck cancer. In addition, in the upper right quadrant of Supplementary Figure S4, “cetuximab resistance”, “cisplatin-resistance”, “erlotinib ", “cisplatin-resistance”, “erlotinib” and “cell hypoxia” belong to the motor themes. These keywords have strong centrality and high density in head and neck cancer resistance research. They are conceptually closely related to other quadrant themes. The keyword categories “microarray” and “MTT assay” in the upper left quadrant have well-defined internal connections, but external connections are not relevant. The keywords in the lower left quadrant have themes that are neither developed nor significant. Topics in the lower right quadrant have relevant keywords to the research area, but are not developed. In summary, we have provided a comprehensive description of the hotspots and trends in drug resistance research in head and neck cancer. This is done through co-occurrence and clustering analysis of keywords.
3.5 Literature co-citation and cluster analysis
Our literature co-citation and clustering analyses provide insights to systematically understand the hotspots of drug resistance research in head and neck cancer, assess the impact of scientific research, and reveal correlations between related subfields. Figure 6A presents the TOP10 most cited authors, with red highlighted authors. Siegel RL’s “Cancer statistics, 2019” (Siegel et al., 2019) and Agrawal N’s “Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1” () are the papers with the two authors with the high centrality. These two papers play a key role in bridging networks of information dissemination and communication. Academically, their contributions are highly influential and leading. Meanwhile, we present the papers that exploded in the field in Figure 6B using red circles based on the above. Further, we count the TOP 10 papers in terms of outbreak intensity in Figure 6C. During 2018–2023, the outbreak intensity of Chen YP () and Chua MLK () papers on Nasopharyngeal carcinoma was 9.86 and 6.84, respectively. This indicates that Nasopharyngeal carcinoma has been the focus of drug-resistant research in head and neck cancer for 5 years and is developing rapidly. In addition, we visualized the shock flow map of citation duration in Figure 6D. We screened the key papers that were consistently cited for more than 4 years. First, Xiao L and Hsieh MJ’s studies on improving cisplatin resistance and sensitivity to radiotherapy in nasopharyngeal carcinoma, respectively, received sustained attention (Xiao et al., 2014; Hsieh et al., 2019). Second, Herbst RS’s study on the effect of the PD-L1 antibody MPDL3280A on patients expressing high levels of PD-L1 in a variety of cancer types has been consistently cited for 6 years (Herbst et al., 2014). Finally, Xing MZ’s research on the mechanism of BRAF V600E mutation in thyroid cancer progression has been profoundly influenced by scholars in the field (Xing et al., 2015). In particular, the microRNA downregulation of Pallante P in thyroid cancer treatment and diagnosis continued to receive attention during 2016–2022 (Pallante et al., 2014). In summary, we dissected the key literature in drug resistance research in head and neck cancer from multiple perspectives. We provided insightful academic references for researchers, policymakers, and the academic community.
FIGURE 6
In addition, clustering analysis by literature co-citation helps us dig deeper into the knowledge structure and research focus of drug resistance research in head and neck cancer. We obtained 9 clusters, #0-#8, after keyword and title clustering and filtering the literature by citespace. We labeled the clusters using LSI and LLR algorithms. The size, silhouette, Mean, LSI, and LLR information of each cluster in the results of keyword clustering of the literature is shown in detail in Table 3. Further, we deeply analyzed the hotspot and field variation of drug resistance research in head and neck cancer. We did this by the dependency between the taxon labeling and the previous taxon. First, in Figure 7A, the time-series changes in the number of publications of the nine taxa are presented, and the vertical coordinates are the LLR and LSI labels of different taxa. Among them, “#1 Cancer Stem Cells” is a cluster containing 257 publications, suggesting that cancer stem cells may be the focus of attention in drug resistance research in head and neck cancer. Secondly, taxa #2-#6 LLR and LSI classification labels were consistent and contained a decreasing number of literature based on the taxon number, reflecting the hot topic of drug resistance research in head and neck cancer. However, taxon #7 represents “Ferroptosis” and “Cispaltin Resistance” respectively, which may indicate that the relationship between iron death and cisplatin resistance mechanism has received attention from scholars. Similarly, taxon #8 may indicate the correlation between drug resistance and ERK pathway in laryngeal squamous carcinoma. Finally, we visualized the dependencies between different clusters in the keyword and title clustering of #0-#8 literature through the citespace “Cluster Dependencies” module in Figure 7B and Supplementary Figure S5A, respectively. By analyzing the dependencies among different clusters, we are able to deduce the evolutionary patterns of the themes of each cluster. Finally, for ease of analysis, we simplify this evolutionary pattern in Figure 7C. Clearly, "#1 Cancer stem cell”, "#2 nasopharyngeal carcinoma” and "#4 thyroid cancer " developed into the "#0 SCCHN” theme. Similarly, the dependency analysis presenting the clustering results of the literature titles in Supplementary Figure S5 showed that the "#0 targeting EGFR resistance network” theme was built on the “#1 stem-like cell” and “#4 thyroid cancer” themes. “ and ”#2 thyroid cancer” clusters.
TABLE 3
| Cluster | Size | Silhouette | mean (Year) | Label (LSI) | Label (LLR) |
|---|---|---|---|---|---|
| 0 | 333 | 0.834 | 2006 | neck cancer; drug resistance; gene copy number; treatment response; predictive marker | stat; pi3k; grb2; pten; plc-gamma | scchn (12.27, 0.001); pten (6.91, 0.01); egfrviii (6.11, 0.05); predictive marker (6.11, 0.05); gene copy number (6.11, 0.05) |
| 1 | 257 | 0.962 | 2008 | oral squamous cell carcinoma; cancer stem cells; side population; sphere formation; to-mesenchymal transition | side population; drug resistance; sphere formation; to-mesenchymal transition; epidermal growth factor receptor | cancer stem cells (21.01, 1.0E-4); oral squamous cell carcinoma (9.11, 0.005); side population (6.51, 0.05); invasion (6.51, 0.05); carbon ion irradiation (6.51, 0.05) |
| 2 | 199 | 0.947 | 2016 | nasopharyngeal carcinoma; cisplatin resistance; fusion genes; microsatellite instability; mir-619-5p | oral squamous cell carcinoma; fusion genes; microsatellite instability; mir-619-5p; cell growth | thyroid cancer (10.04, 0.005); nasopharyngeal carcinoma (9.45, 0.005); cetuximab (6.78, 0.01); tumor microenvironment (6.46, 0.05); extracellular vesicles (6.46, 0.05) |
| 3 | 188 | 0.956 | 2009 | epidermal growth factor receptor; oral squamous cell carcinoma; sphere formation; cancer stem cells; stat | pi3k; grb2; pten; plc-gamma; c-met | epidermal growth factor receptor (5.82, 0.05); head and neck (4.75, 0.05); receptor tyrosine kinase (4.75, 0.05); review (4.75, 0.05); antibody (4.75, 0.05) |
| 4 | 185 | 0.947 | 2013 | thyroid cancer; braf mutation; braf inhibitors; radioactive iodine resistance; radioiodine refractoriness | drug resistance; signal transduction; molecular mechanisms; sodium iodide symporter; mouse model | thyroid cancer (38.77, 1.0E-4); vemurafenib (12.2, 0.001); kinase inhibitors (12.2, 0.001); drug resistance (11.52, 0.001); radioactive iodine refractory (8.12, 0.005) |
| 5 | 136 | 0.977 | 2012 | neck cancer; paclitaxel resistance; targeted therapy; immune infiltration; pi3 kinase class iii | cisplatin resistance; glutamate antiporter; lipid reactive oxygen species; pi3 kinase class iii; epigallocatechin gallate | ferroptosis (17.71, 1.0E-4); reactive oxygen species (13.68, 0.001); nrf2 (9.1, 0.005); resveratrol (9.1, 0.005); human cisplatin-resistant oral cancer car cells (9.1, 0.005) |
| 6 | 128 | 0.997 | 2008 | insulin resistance; igfbp-3 gene polymorphisms; differentiated thyroid cancer | differentiated thyroid cancer; insulin resistance; igfbp-3 gene polymorphisms | insulin resistance (18.2, 1.0E-4); risk of recurrence (9, 0.005); irs-1 (9, 0.005); igfbp-3 gene polymorphisms (9, 0.005); argentina (9, 0.005) |
| 7 | 128 | 0.976 | 2004 | oral squamous cell carcinoma; cellular inhibitor; apoptosis protein; oral squamous cell carcinoma cell lines; drug resistance | oral squamous cell carcinoma cell lines; drug resistance; cellular inhibitor; apoptosis protein; oral squamous cell carcinoma | oral squamous cell carcinoma cell lines (9.2, 0.005); cellular inhibitor of apoptosis protein 2 (9.2, 0.005); microarray (9.2, 0.005); mtt assay (9.2, 0.005); cddp (6.45, 0.05) |
| 8 | 126 | 1 | 2007 | larynx cancer; dna methylation; plant polyphenols; akt pathway; hep-2 cells | akt pathway; hep-2 cells; laryngeal cancer; larynx cancer; dna methylation | erk signaling (8.82, 0.005); akt pathway (8.82, 0.005); inpp4b (8.82, 0.005); chemoprevention (8.82, 0.005); hep-2 cells (8.82, 0.005) |
Literature cluster analysis: #0-#8 cluster sizes, silhouette values, means, and labels.
FIGURE 7
Taken together, the co-citation and clustering analysis of the literature in the field of head and neck cancer drug resistance research provided us with a deep insight into the research hotspots and the evolution of the key #0 to #8 clusters.
3.6 Analysis of journals and co-cited journals
We analyzed journals in the field of drug resistance in head and neck cancer through Citespace’s “Overlay Maps”. Overlap analysis helps identify high-impact journals and papers to provide research direction. Figure 8A provides the necessary knowledge base for citing journals. The yellow #4 and green #2 paths in the journal biplot overlay mapping indicate that research published in journals related to “Molecular, Biological and Immunological” and “Medical, Medical and Clinical”, respectively, is usually cited in journals in the “Molecular, Biological and Genetic” field, which is colored #8 in pink. Specifically, the cited articles in “Molecular, Biology and Genetics” were primarily from Cancer Research and Clinical Cancer Research journals. In addition, we counted the impact factors, JCR quartiles, and open access (OA) information of the top 20 cited journals in Supplementary Table S8. These findings highlight the interconnectedness of different fields in the study of drug resistance in head and neck cancer. They also highlight the importance of interdisciplinary research in advancing scientific knowledge.
FIGURE 8
Furthermore, we analyzed the highly published and influential journals in the field of drug resistance in head and neck cancer. We used the “Bradford’s Law” module of the bibloshiny tool. According to Bradford’s Law, a small number of core journals contribute the majority of research output in the field. In contrast, most journals contribute relatively little. The left side of Figure 8B presents the overall picture and the right side shows the core journals. There are 20 core journals on the panel, of which the TOP3 journals are Oncotarget, Cancers, and Clinical Cancer Research. Further, we count the publication volume, H-index, impact factor, partitioning, and OA index of these 20 core journals in the field in Table 4. The first thing to note is that the journal Oncotarget has open access (OA) attributes and ranks first in the field with 25 articles and 19 H-indexes in the area of head and neck cancer drug resistance. However, it is worth pointing out that the journal is not included in the Science Citation Index (SCI) journal category. Second, Clinical Cancer Research demonstrated the highest overall drug resistance in head and neck cancer. This was in terms of number of articles, H-index, impact factor, and partitioning. Finally, of these 20 core journals, 11 are in the high impact factor quartile (Q1), 6 are in the medium quartile (Q2), and 2 are in the lower quartile (Q3). Of these, eight journals have an impact factor of more than 5, while seven are open access (OA) journals. Taken together, we gained more comprehensive access to the latest research findings about drug resistance in head and neck cancer. We did this by focusing exclusively on core journals in this area.
TABLE 4
| Rank | Journal | Counts | H-index | If (JCR 2022) | JCR quatile | OA |
|---|---|---|---|---|---|---|
| 1 | ONCOTARGET | 25 | 19 | - | - | Yes |
| 2 | CANCERS | 19 | 8 | 5.2 | Q1 | Yes |
| 3 | CLINICAL CANCER RESEARCH | 19 | 17 | 11.5 | Q1 | No |
| 4 | INTERNATIONAL JOURNAL OF ONCOLOGY | 18 | 14 | 5.2 | Q1 | No |
| 5 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 17 | 8 | 5.6 | Q1 | Yes |
| 6 | ONCOLOGY REPORTS | 16 | 12 | 4.2 | Q2 | No |
| 7 | CANCER LETTERS | 15 | 13 | 9.7 | Q1 | No |
| 8 | FRONTIERS IN ONCOLOGY | 14 | 7 | 4.7 | Q2 | Yes |
| 9 | HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 14 | 10 | 2.9 | Q1 | No |
| 10 | ORAL ONCOLOGY | 14 | 11 | 4.8 | Q1 | No |
| 11 | MOLECULAR CANCER THERAPEUTICS | 12 | 11 | 5.7 | Q2 | No |
| 12 | ONCOLOGY LETTERS | 12 | 8 | 2.9 | Q3 | No |
| 13 | PLOS ONE | 10 | 8 | 3.7 | Q2 | Yes |
| 14 | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 8 | 5 | 3.1 | Q2 | No |
| 15 | BMC CANCER | 8 | 6 | 3.8 | Q2 | Yes |
| 16 | CANCER RESEARCH | 8 | 8 | 11.2 | Q1 | No |
| 17 | ENDOCRINE | 8 | 5 | 3.7 | Q3 | No |
| 18 | THYROID | 8 | 7 | 6.6 | Q1 | No |
| 19 | BIOENGINEERED | 7 | 5 | 4.9 | Q1 | Yes |
| 20 | BIOMEDICINE and PHARMACOTHERAPY | 7 | 6 | 7.5 | Q1 | No |
Top 20 journals: H-index, JCR impact factor, quartiles and OA details.
4 Discussion
4.1 Pharmacotherapeutic strategies for head and neck cancer: Present and future
For patients with locally advanced and recurrent metastatic head and neck cancer, surgery and drug combination therapy have become the current mainstream recommended regimen. In Figure 9, we have combined the 2022 American Society of Clinical Oncology (ASCO) meeting and the 2023 Chinese Society of Clinical Oncology (CSCO) guidelines on head and neck cancer to provide an overview of current treatment strategies and drug combination options. In addition, we refer to new advances in head and neck cancer treatment presented at the ASCO 2023 meeting to guide future treatment regimens.
FIGURE 9
In the area of drug therapy for localized head and neck cancer, four academics’ protocols were included in the category of “future therapies”. Prof. Rosenberg says a neoadjuvant regimen based on nivolumab in combination with paclitaxel and carboplatin has shown significant survival and local control benefits in patients with highly advanced HPV-negative squamous head and neck cancer (Rosenberg et al., 2023). Meanwhile, the experimental II regimen introduced by Prof. Ferrarotto in the field of laryngeal cancer treatment showed excellent advantages in terms of laryngeal preservation rate, recurrence rate and survival rate (Ferrarotto et al., 2023). In addition, experimental regimens iii and iv proposed by Chinese doctors Xiao Min and Gui Lin have shown significant efficacy in the treatment of localized head and neck cancer (Gui et al., 2023; Ou et al., 2023).
The protocols of three authors have been included in the category of “future treatments” for recurrent metastatic head and neck cancers. First, a study from France treated 64 patients who could not receive cisplatin-based chemotherapy with regimen i, showing safety and efficacy in a vulnerable population (). Second, Prof. Hanna presented regimen ii (containing the EGFR/TGFβ bifunctional inhibitor BCA101 in combination with pembrolizumab), which showed significant efficacy in HPV-negative patients (Hanna et al., 2023). Finally, Dr. Xue Liqiong shared regimen iii (including the EGFR/HER3 bispecific antibody SI-B001 in combination with paclitaxel), which presented significant efficacy in patients who had not received paclitaxel (Xue et al., 2023). Of particular note is the growing importance of “de-chemotherapy” in the treatment of recurrent/metastatic head and neck cancer. In the 2023 edition of the CSCO Head and Neck Cancer Treatment Guidelines, targeted therapy in combination with immunotherapy is recommended as a level III therapy. This indicates that this treatment modality is being explored. As a result, recurrent/metastatic head and neck cancer may move toward a " De-chemotherapy " era in the future. These options are included in the category of “future treatments” for locally advanced head and neck cancer.
Additionally, targeted therapy combined with immunotherapy is recommended as a level III recommendation in the CSCO Head and Neck Cancer Treatment Guidelines 2023. This indicates that this treatment modality is being explored. As a result, head and neck cancer treatment may progress toward a " De-chemotherapy " era in the future.
4.2 Global growth trends and drug resistance research in head and neck cancer
We statistically analyzed head and neck cancer drug resistance trends from 2000 to 2023. We paid particular attention to the significant growth in recent years. Annual citation trends show three phases of fluctuation, plateauing, and decreasing over time. These phases may be due to low-quality research, fragmentation of the field, citation lag, changes in research direction, and potential data deficiencies or short-term fluctuations.
Continued global investment and in-depth exploration of basic drug resistance research in head and neck cancer has provided crucial impetus for advancing drug resistance research in head and neck cancer. In recent years, worldwide research on drug resistance in head and neck cancer has made progress, focusing on the following three aspects.
(1) Targeted therapy: This therapy kills tumor cells by inhibiting specific targets of tumor cells. Although targeted agents such as erlotinib and cetuximab have gained approval in the treatment of head and neck cancer, patients are often challenged by resistance to the targeted agents (Ratushny et al., 2009). Studies have revealed resistance mechanisms, including genetic mutations and signaling pathway reorganization (; Li et al., 2022; ). These findings highlight limitations to therapy effectiveness. More in-depth studies are urgently needed to find effective strategies to overcome drug resistance to improve the survival of head and neck cancer patients.
(2) Immunotherapy: Currently, the main treatments are PD-1/PD-L1 inhibitors (Miraki Feriz et al., 2023), CTLA-4 inhibitors (Tasaki et al., 2023), NK cell therapy (; Jung et al., 2023), and a combination of these approaches (Sperling et al., 2023). In addition, vaccine therapies aim to stimulate the patient’s defense system to respond specifically to the tumor (; Santegoets et al., 2023). Research into head and neck cancer vaccines is ongoing. However, immune selection eliminates T-cell-sensitive subclones and drug-resistant subclones. It has been found that this may be caused by multiple immune escape mechanisms that limit therapeutic efficacy (Lee and Allen, 2020). To overcome immune resistance, researchers need to gain a deeper understanding of molecular mechanisms and develop more targeted therapeutic strategies. This will improve immunotherapy durability and efficacy for head and neck cancer.
(3) Novel chemotherapeutic drugs: In recent years, novel chemotherapeutic drugs have been developed, such as salvia divinorum extract (Yang et al., 2017), tetrandrine (), fluorouracil derivatives (Vermorken et al., 2011; Oertel et al., 2012) and anti-angiogenic drugs. Research shows that these novel chemotherapeutic drugs can effectively improve head and neck cancer patients’ therapeutic effect (Murányi et al., 2023).
Furthermore, individualized treatment, including stem cell (Küçükgüven and Çelebi-Saltik, 2021; ) and gene therapy. Medical professionals can use systematic genomic analysis to understand cancer characteristics and develop personalized treatment plans. In summary, global research on drug resistance in head and neck cancer has progressed, yet significant challenges remain. Future research should focus on innovating more effective treatments to improve patient prognosis.
4.3 Contributions by states, institutions and authors
This paper statistically analyzes international collaborations in head and neck cancer drug resistance research at three levels: country, institution and author. Firstly, China, the United States and Japan lead in head and neck cancer drug resistance research. This is with the number of publications and citation frequency ranking among the top three. Among them, China has an absolute advantage in the number of publications, and the United States has an obvious advantage in the frequency of citations. Secondly, in terms of institutions, China, the United States, and Japan are the main contributors to drug resistance research in head and neck cancer. China Medical University is the leading university in China. The United States plays a key role in international collaborations. M.D. Anderson Cancer Research Center is very significant in the field because it provides key support between the various clusters. Finally, in terms of authors, the Top10 authors, Grandis Jennifer R and Yang Jai-Sing lead the volume of publications, while Osmak Maja, Kim Eun Hye, Roh Jong-Lyel, and Lu Chi-Cheng are noted for their excellent citation performance. Through LLR clustering analysis, the TOP10 authors focused on five major research directions. This demonstrated their profound impact on head and neck cancer drug resistance research. Detailed statistics on the TOP10 authors’ publication volume, academic index, and influence in the field highlight their notable academic and clinical contributions.
4.4 Research hotspots identified through keyword and literature clustering
Head and neck cancer drug resistance studies revealed research hotspots through keyword co-occurrence analysis. First, VOSViewer counted and visualized keywords. This indicated that treatment method, drug resistance type, and research topic were the three major categories of keywords. Second, LLR and LSI clustering analysis and visualization were used to obtain 16 clusters. These clusters included multidrug resistance in nasopharyngeal carcinoma, the application of RT-PCR in drug resistance research, and the relationship between coenzyme Q-related genes and drug resistance. Finally, the annual keyword frequency heatmap revealed therapeutic focus (Paclitaxel, Immunotherapy, Cisplatin Resistance, Cetuximab), emerging themes (MicroRNA, Metastasis, Ferroptosis, AKT), and motor themes (Cetuximab Resistance, Cisplatin-resistance, Erlotinib, Cell Hypoxia), providing a comprehensive understanding of hotspots and trends in head and neck cancer resistance research. Specifically, emerging areas of cetuximab resistance research in head and neck cancer involve EFNB2 (), NRG1 (Iida et al., 2022), TRIP13-pY56 (), and mathematical resistance prediction models (). Furthermore, resveratrol (), miR-196a (Qin et al., 2019), ferroptosis (Roh et al., 2017; Shin et al., 2018), and photodynamic therapy (Lu et al., 2014) have been investigated specifically as agents for reversing cisplatin resistance in head and neck cancer.
Literature co-citation cluster analysis deepened drug resistance research knowledge structure and focused on head and neck cancer. First, citespace clustered literature keywords and titles to generate nine clusters. It labeled the cluster labels using LSI and LLR algorithms. Second, the hotspots and field evolution of drug resistance research in head and neck cancer were revealed by analyzing the taxon labels and their dependencies. #1 focuses on cancer stem cells, #2-#6 reflect hot topics, while #7 involves Ferroptosis and Cisplatin Resistance, and #8 may involve laryngeal squamous carcinoma drug resistance with the ERK pathway (Kim et al., 2012). Chemotherapeutic agents may increase stem-like cells in cancer tissue (). Therefore, combining conventional chemotherapeutic agents with stemness modulators inhibits cancer cell proliferation and reduces recurrence. By combining a sphingosine kinase one antagonist (FTY720) with paclitaxel, the levels of stemness-associated proteins in oral squamous carcinoma cells can be effectively reduced, which in turn achieves anti-cancer effects (Torres et al., 2024). Finally, the Citespace “Cluster Dependencies” module was used to visualize the dependencies between clusters, simplifying the evolutionary pattern and revealing the research focus trajectory (Li and Li, 2024). This provides a deep insight into the hot trends and evolutionary relationships between taxa in head and neck cancer drug resistance research.
4.5 Head and neck Cancer Research: The most influential journal
We analyzed journals in the field of drug resistance in head and neck cancer through Citespace’s “Overlay Maps”, revealing the importance of interdisciplinary research. The overlap analysis between cited journals showed that research and citations published in the fields of “Molecular, Biology and Immunology” and “Medicine, Medical and Clinical” were mainly concentrated in journals related to “Molecular, Biology and Genetics”, emphasizing the interconnections between different fields. In addition, we analyzed the core journals using Bradford’s Law and found that Oncotarget, Cancers, and Clinical Cancer Research were the main influential journals in the field of drug resistance in head and neck cancer, with Clinical Cancer Research showing the highest level of overall strength, and Oncotarget demonstrating the highest level of open access strength, and Clinical Cancer Research showing the highest level of open access strength. Oncotarget was also noted for its open access attributes and high impact. The specific attributes of these core journals are critical for obtaining the latest research results on drug resistance in head and neck cancer.
4.6 Research strengths and limitations
This study has the following strengths.
(1) To the extent of our knowledge, this study is the first bibliometric literature that comprehensively assesses global drug resistance studies in head and neck cancer.
(2) We used the most reliable WOSCC database for bibliometric analysis (Liu et al., 2024b; Zhang et al., 2024). This database has broad coverage, high-quality literature, standardized data, and comprehensive search functionality.
(3) We comprehensively used a variety of analytical tools such as Citespace, R package bibliometric, VOSviewer, SCImago Graphica, and MapEquation to econometrically analyze the literature on drug resistance in head and neck cancer, which provided comprehensive and in-depth scholarly insights to help researchers understand the research dynamics, partnerships, and hotspot trends in drug resistance in head and neck cancer in a morin-depthve way.
Shortcomings of this study.
(1) Although a single database (WOSCC) was used in this study for bibliometric analysis of head and neck cancer drug resistance studies. However, several studies have shown that this database is considered an excellent resource for bibliometric studies in various disciplines.
(2) Given the time lag in the inclusion of papers in the WOSCC database, this study could not cover all papers published in 2023. Therefore, it is impossible to present the latest research results on drug resistance in head and neck cancer.
5 Conclusion
This study can help researchers understand the global focus and trends in head and neck cancer drug resistance research from 2000 to December 2023. First, the statistical analysis of the 2000–2023 trends in the field of head and neck cancer drug resistance research shows that the trend of publications has increased significantly. However, the citation trend goes through three stages of fluctuation, stabilization, and decreasing year by year. Then, China, the United States, and Japan lead the head and neck cancer drug resistance research, and China Medical University has a leading position at the institutional level, and the Top 10 authors have significant outputs in the five research directions, which highlights their significant contributions in both academic and clinical aspects. Second, the keyword co-occurrence and co-citation analysis of Head and Neck Cancer Drug Resistance Research comprehensively reveals the research hotspots, trends and knowledge structure, and provides a deep insight into the evolution of the field. Finally, the “Overlay Maps” and Bradford’s Law analyses reveal the cross-impact and core journals in the field of drug resistance in head and neck cancer, providing directions for comprehensive access to the latest research results. In conclusion, this literature provides researchers with an in-depth understanding of the current status and hot trends of drug resistance research in head and neck cancer worldwide.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.
Author contributions
QH: Conceptualization, Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Visualization, Writing–original draft, Writing–review and editing. JS: Data curation, Supervision, Writing–original draft. JL: Conceptualization, Data curation, Supervision, Writing–original draft. YF: Conceptualization, Investigation, Visualization, Writing–original draft. ZL: Conceptualization, Data curation, Funding acquisition, Writing–original draft. HG: Conceptualization, Data curation, Writing–original draft. XG: Conceptualization, Data curation, Writing–original draft. XX: Conceptualization, Funding acquisition, Investigation, Writing–original draft. HL: Funding acquisition, Supervision, Writing–original draft. LZ: Data curation, Funding acquisition, Supervision, Writing–original draft. CZ: Data curation, Investigation, Resources, Supervision, Writing–original draft.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Basic Research Program of Shanxi Province (Free Exploration) (No. 202203021212036, 202203021211015, 202203021212032, 202203021212034), Scientific and Technological Innovation Programs of Higher Education Institutions in Shanxi (No. 2022L133, 2022L135).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1375110/full#supplementary-material
References
1
AgrawalN.FrederickM. J.PickeringC. R.BettegowdaC.ChangK.LiR. J.et al (2011). Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science333, 1154–1157. 10.1126/science.1206923
2
AriaM.CuccurulloC. (2017). bibliometric: an R-tool for comprehensive science mapping analysis. J. Informetr.11, 959–975. 10.1016/j.joi.2017.08.007
3
AyusoJ. M.FarooquiM.Virumbrales-MuñozM.DeneckeK.RehmanS.SchmitzR.et al (2023). Microphysiological model reveals the promise of memory-like natural killer cell immunotherapy for HIV± cancer. Nat. Commun.14, 6681. 10.1038/s41467-023-41625-8
4
BanerjeeR.LiuM.BellileE.SchmitdL. B.GotoM.HutchinsonM.-K. N. D.et al (2022). Phosphorylation of TRIP13 at Y56 induces radiation resistance but sensitizes head and neck cancer to cetuximab. Mol. Ther.30, 468–484. 10.1016/j.ymthe.2021.06.009
5
BiswalS.PandaM.SahooR. K.TripathiS. K.BiswalB. K. (2023). Tumour microenvironment and aberrant signaling pathways in cisplatin resistance and strategies to overcome in oral cancer. Arch. Oral Biol.151, 105697. 10.1016/j.archoralbio.2023.105697
6
BommireddyR.MunozL. E.KumariA.HuangL.FanY.MonterrozaL.et al (2020). Tumor membrane vesicle vaccine augments the efficacy of anti-PD1 antibody in immune checkpoint inhibitor-resistant squamous cell carcinoma models of head and neck cancer. Nato. Adv. Sci. Inst. Se.8, 182. 10.3390/vaccines8020182
7
ByunJ.-Y.HuangK.LeeJ. S.HuangW.HuL.ZhengX.et al (2022). Targeting HIF-1α/NOTCH1 pathway eliminates CD44+ cancer stem-like cell phenotypes, malignancy, and resistance to therapy in head and neck squamous cell carcinoma. Oncogene41, 1352–1363. 10.1038/s41388-021-02166-w
8
CárdenasS. D.ReznikC. J.RanaweeraR.SongF.ChungC. H.FertigE. J.et al (2022). Model-informed experimental design recommendations for distinguishing intrinsic and acquired targeted therapeutic resistance in head and neck cancer. npj Syst. Biol. Appl.8, 32. 10.1038/s41540-022-00244-7
9
ChanC.-Y.HongS.-C.ChangC.-M.ChenY.-H.LiaoP.-C.HuangC.-Y. (2023). Oral squamous cell carcinoma cells with acquired resistance to erlotinib are sensitive to anti-cancer effect of quercetin via pyruvate kinase M2 (PKM2). Cells12, 179. 10.3390/cells12010179
10
ChangC.-W.ChenC.ChangC.-W.ChiuP.-Y.YangJ.-S.ChenF.-A. (2023). Effects of tetrandrine on the apoptosis of cisplatin-resistant oral cancer cells. Pharmacogn. Mag.19, 295–302. 10.1177/09731296231158699
11
ChangW.-S.TsaiC.-W.YangJ.-S.HsuY.-M.ShihL.-C.ChiuH.-Y.et al (2021). Resveratrol inhibited the metastatic behaviors of cisplatin-resistant human oral cancer cells via phosphorylation of ERK/p-38 and suppression of MMP-2/9. J. Food Biochem.45, e13666. 10.1111/jfbc.13666
12
ChaudharyR. K.PatilP.MatetiU. V.AlagundagiD. B.ShettyV. (2023a). Theranostic potential of EFNB2 for cetuximab resistance in head and neck cancer. Indian J. Otolaryngol. Head. Neck Surg.75, 1923–1936. 10.1007/s12070-023-03739-9
13
ChaudharyV.ChaudharyN.MathewsS.SinghR. D. (2023b). Human papilloma virus-associated oral pharyngeal squamous cell carcinoma: prevalence, prevention, and awareness of vaccination in the Indian population. Crit. Rev. Oncog.28, 63–72. 10.1615/CritRevOncog.2023048944
14
ChenC.Ibekwe-SanJuanF.HouJ. (2010). The structure and dynamics of Co-citation clusters: a multiple-perspective Co-citation analysis. J. Am. Soc. Inf. Sci.61, 1386–1409. 10.1002/asi.21309
15
ChenX.GaoW.YinG.GuoW.HuangJ.HuangZ.et al (2021). Phospho-EGFRTyr992 is synergistically repressed by co-inhibition of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K), which attenuates resistance to erlotinib in head and neck cancer cells. Ann. Transl. Med.9, 1455. 10.21037/atm-21-4335
16
ChenY.-P.ChanA. T. C.LeQ.-T.BlanchardP.SunY.MaJ. (2019). Nasopharyngeal carcinoma. Lancet394, 64–80. 10.1016/S0140-6736(19)30956-0
17
ChengK.ZhangH.GuoQ.ZhaiP.ZhouY.YangW.et al (2022). Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: a bibliometric study. Front. Immunol.13, 975695. 10.3389/fimmu.2022.975695
18
ChuaM. L. K.WeeJ. T. S.HuiE. P.ChanA. T. C. (2016). Nasopharyngeal carcinoma. Lancet387, 1012–1024. 10.1016/S0140-6736(15)00055-0
19
CserepesM.NelhűbelG. A.Meilinger-DobraM.HerczegA.TürkD.HegedűsZ.et al (2022). EGFR R521K polymorphism is not a major determinant of clinical cetuximab resistance in head and neck cancer. Cancers (Basel)14, 2407. 10.3390/cancers14102407
20
DoghishA. S.El-MahdyH. A.IsmailA.HegazyM.MokhtarM. M.ElkhawagaS. Y.et al (2023). Significance of miRNAs on the thyroid cancer progression and resistance to treatment with special attention to the role of cross-talk between signaling pathways. Pathol. Res. Pract.243, 154371. 10.1016/j.prp.2023.154371
21
DornaD.PaluszczakJ. (2023). Targeting cancer stem cells as a strategy for reducing chemotherapy resistance in head and neck cancers. J. Cancer Res. Clin. Oncol.149, 13417–13435. 10.1007/s00432-023-05136-9
22
DumaisS. T. (2004). Latent semantic analysis. Annu. Rev. Inf. Sci.38, 188–230. 10.1002/aris.1440380105
23
EdlerD.BohlinL.RosvallM. (2017). Mapping higher-order network flows in memory and multilayer networks with infomap. Lect. Notes. Comput. Sc.10, 112. 10.3390/a10040112
24
EggheL. (2006). Theory and practise of the g-index. Scientometrics69, 131–152. 10.1007/s11192-006-0144-7
25
FayetteJ.CropetC.GautierJ.ToullecC.BurgyM.BruyasA.et al (2023). Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies. J. Clin. Oncol.41, 6003. 10.1200/JCO.2023.41.16_suppl.6003
26
FerrarottoR.JohnsonF. M.HutchesonK. A.SuiD.JohnsonJ. M.EbersoleB.et al (2023). Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results. J. Clin. Oncol.41, 6008. 10.1200/JCO.2023.41.16_suppl.6008
27
GaoZ.ZhangY.ZhouH.LvJ. (2020). Baicalein inhibits the growth of oral squamous cell carcinoma cells by downregulating the expression of transcription factor Sp1. Int. J. Oncol.56, 273–282. 10.3892/ijo.2019.4894
28
GloverS.DixonP. (2004). Likelihood ratios: a simple and flexible statistic for empirical psychologists. Psychon. B. Rev.11, 791–806. 10.3758/BF03196706
29
GuiL.LiuS.WangX.ZhangY.HeX. (2023). Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: a single-arm, phase II trial. J. Clin. Oncol.41, 6087. 10.1200/JCO.2023.41.16_suppl.6087
30
GuoJ.YouH.LiD. (2019). Baicalein exerts anticancer effect in nasopharyngeal carcinoma in vitro and in vivo. Oncol. Res.27, 601–611. 10.3727/096504018X15399945637736
31
HanQ.LiZ.FuY.LiuH.GuoH.GuanX.et al (2023). Analyzing the research landscape: mapping frontiers and hot spots in anti-cancer research using bibliometric analysis and research network pharmacology. Front. Pharmacol.14, 1256188. 10.3389/fphar.2023.1256188
32
HannaG. J.KaczmarJ. M.ZandbergD. P.WongD. J. L.YilmazE.ShermanE. J.et al (2023). Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma. J. Clin. Oncol.41, 6005. 10.1200/JCO.2023.41.16_suppl.6005
33
HarringtonK. J.CohenE. E. W.SoulièresD.DinisJ.LicitraL.AhnM.-J.et al (2023). Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): subgroup analysis by pattern of disease recurrence. Oral Oncol.147, 106587. 10.1016/j.oraloncology.2023.106587
34
HarzingA.-W. (2016). Reflections on the H-index. Leadersh.1, 101–106. Available at: https://harzing.com/publications/white-papers/reflections-on-the-h-index (Accessed January 5, 2024)
35
HerbstR. S.SoriaJ.-C.KowanetzM.FineG. D.HamidO.GordonM. S.et al (2014). Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature515, 563–567. 10.1038/nature14011
36
HirschJ. E. (2005). An index to quantify an individual’s scientific research output. Proc. Natl. Acad. Sci. U. S. A.102, 16569–16572. 10.1073/pnas.0507655102
37
HsiehM.-J.WangC.-W.LinJ.-T.ChuangY.-C.HsiY.-T.LoY.-S.et al (2019). Celastrol, a plant-derived triterpene, induces cisplatin-resistance nasopharyngeal carcinoma cancer cell apoptosis though ERK1/2 and p38 MAPK signaling pathway. Phytomedicine58, 152805. 10.1016/j.phymed.2018.12.028
38
IidaM.McDanielN. K.KosteckiK. L.WelkeN. B.KranjacC. A.LiuP.et al (2022). AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer22, 447. 10.1186/s12885-022-09511-6
39
JhaA.AlamM.KashyapT.NathN.KumariA.PramanikK. K.et al (2023). Crosstalk between PD-L1 and Jak2-Stat3/MAPK-AP1 signaling promotes oral cancer progression, invasion and therapy resistance. Int. Immunopharmacol.124, 110894. 10.1016/j.intimp.2023.110894
40
JumaniyazovaE.LokhoninaA.DzhalilovaD.KosyrevaA.FatkhudinovT. (2022). Immune cells in head-and-neck tumor microenvironments. J. Personalized Med.12, 1521. 10.3390/jpm12091521
41
JungE. K.ChuT.-H.KimS.-A.VoM.-C.NguyenV.-T.LeeK.-H.et al (2023). Efficacy of natural killer cell therapy combined with chemoradiotherapy in murine models of head and neck squamous cell carcinoma. CytotherapyS1465-3249 (23), 242–251. 10.1016/j.jcyt.2023.11.002
42
KimJ.-S.YunH. S.UmH.-D.ParkJ. K.LeeK.-H.KangC.-M.et al (2012). Identification of inositol polyphosphate 4-phosphatase type II as a novel tumor resistance biomarker in human laryngeal cancer HEp-2 cells. Cancer Biol. Ther.13, 1307–1318. 10.4161/cbt.21788
43
KüçükgüvenM. B.Çelebi-SaltikB. (2021). Different aspects of head and neck squamous cell carcinoma: cancer stem cells, their niche and targeted therapy. Curr. Stem Cell Res. Ther.16, 286–306. 10.2174/1574888X15666200921163326
44
LeeM. Y.AllenC. T. (2020). Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer. Head. Neck42, 2722–2733. 10.1002/hed.26158
45
LiH.LiB. (2024). The state of metaverse research: a bibliometric visual analysis based on CiteSpace. J. Big Data11, 14–23. 10.1186/s40537-024-00877-x
46
LiH.PeyserN. D.ZengY.HaP. K.JohnsonD. E.GrandisJ. R. (2022). NSAIDs overcome PIK3CA mutation-mediated resistance to EGFR inhibition in head and neck cancer preclinical models. Cancers (Basel)14, 506. 10.3390/cancers14030506
47
LiY. (2021). Pyrvinium pamoate can overcome artemisinin’s resistance in anaplastic thyroid cancer. BMC Complement. Med. Ther.21, 156. 10.1186/s12906-021-03332-z
48
LiuS.QinZ.MaoY.WangN.ZhangW.WangY.et al (2024a). Pharmacological inhibition of MYC to mitigate chemoresistance in preclinical models of squamous cell carcinoma. Theranostics14, 622–639. 10.7150/thno.88759
49
LiuY.ChenC.ZhouY.ZhangN.LiuS. (2024b). Twenty years of research on borderline personality disorder: a scientometric analysis of hotspots, bursts, and research trends. Front. Psychiatry15, 1361535. 10.3389/fpsyt.2024.1361535
50
LuK.HeC.LinW. (2014). Nanoscale metal-organic framework for highly effective photodynamic therapy of resistant head and neck cancer. J. Am. Chem. Soc.136, 16712–16715. 10.1021/ja508679h
51
MarcoD. F.GianlucaA.MariagraziaT.LucaE. P. (2022). Overcoming immune-resistance in laryngeal cancer: a case report of the abscopal effect and nivolumab beyond progression. Immunotherapy14, 1089–1095. 10.2217/imt-2021-0309
52
MarounC. A.MandalR. (2021). Anti-PD-1 immune checkpoint blockade for head and neck cancer: biomarkers of response and resistance. Otolaryngol. Clin. North Am.54, 751–759. 10.1016/j.otc.2021.04.006
53
Measuring Scholarly Impact: Methods and Practice | SpringerLink (2024). Measuring scholarly impact: methods and practice | SpringerLink. Available at: https://link.springer.com/book/10.1007/978-3-319-10377-8 (Accessed January 6, 2024).
54
Miraki FerizA.BahrainiF.KhosrojerdiA.AzarkarS.SajjadiS. M.HosseiniGolE.et al (2023). Deciphering the immune landscape of head and neck squamous cell carcinoma: a single-cell transcriptomic analysis of regulatory T cell responses to PD-1 blockade therapy. PLOS One18, e0295863. 10.1371/journal.pone.0295863
55
MurányiJ.DuróC.GurbiB.MóraI.VargaA.NémethK.et al (2023). Novel erlotinib-chalcone hybrids diminish resistance in head and neck cancer by inducing multiple cell death mechanisms. Int. J. Mol. Sci.24, 3456. 10.3390/ijms24043456
56
OertelK.SpiegelK.SchmalenbergH.DietzA.MaschmeyerG.KuhntT.et al (2012). Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). BMC Cancer12, 483. 10.1186/1471-2407-12-483
57
OuX.HeX.WangY.LuX.YingH.JiD.et al (2023). Induction chemotherapy and toripalimab for larynx preservation in resectable locally advanced laryngeal/hypopharyngeal carcinoma: preliminary results of INSIGHT study. J. Clin. Oncol.41, 6068. 10.1200/JCO.2023.41.16_suppl.6068
58
PallanteP.BattistaS.PierantoniG. M.FuscoA. (2014). Deregulation of microRNA expression in thyroid neoplasias. Nat. Rev. Endocrinol.10, 88–101. 10.1038/nrendo.2013.223
59
Perianes-RodriguezA.WaltmanL.van EckN. J. (2016). Constructing bibliometric networks: a comparison between full and fractional counting. J. Informetr.10, 1178–1195. 10.1016/j.joi.2016.10.006
60
QiaoX.ZhuL.SongR.ShangC.GuoY. (2023). CD44 occurring alternative splicing promotes cisplatin resistance and evokes tumor immune response in oral squamous cell carcinoma cells. Oncol31, 101644. 10.1016/j.tranon.2023.101644
61
QinX.GuoH.WangX.ZhuX.YanM.WangX.et al (2019). Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol.20, 12. 10.1186/s13059-018-1604-0
62
RatushnyV.AstsaturovI.BurtnessB. A.GolemisE. A.SilvermanJ. S. (2009). Targeting EGFR resistance networks in head and neck cancer. Cell. Signal.21, 1255–1268. 10.1016/j.cellsig.2009.02.021
63
RohJ.-L.KimE. H.JangH.ShinD. (2017). Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol.11, 254–262. 10.1016/j.redox.2016.12.010
64
RosenbergA.JulooriA.AgrawalN.CursioJ.JelinekM. J.CiprianiN.et al (2023). Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): the DEPEND trial. J. Clin. Oncol.41, 6007. 10.1200/JCO.2023.41.16_suppl.6007
65
RousseeuwP. J. (1987). Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. J. Comput. Appl. Math.20, 53–65. 10.1016/0377-0427(87)90125-7
66
SantegoetsS. J.StolkA.WeltersM. J. P.van der BurgS. H. (2023). The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival. Cell Rep. Med.4, 101262. 10.1016/j.xcrm.2023.101262
67
ShinD.KimE. H.LeeJ.RohJ.-L. (2018). Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic. Biol. Med.129, 454–462. 10.1016/j.freeradbiomed.2018.10.426
68
SiegelR. L.MillerK. D.JemalA. (2019). Cancer statistics, 2019. Ca. Cancer J. Clin.69, 7–34. 10.3322/caac.21551
69
SperlingG.ShatilaM.VaratharajaluK.LuY.AltanM.ZhouY.et al (2023). Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors. J. Cancer Res. Clin. Oncol.149, 17597–17605. 10.1007/s00432-023-05461-z
70
StabileL. P.HeG.LuiV. W. Y.ThomasS.HenryC.GubishC. T.et al (2013). c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin. Cancer Res.19, 380–392. 10.1158/1078-0432.CCR-12-1555
71
TangB.DongY. (2023). Network pharmacology and bioinformatics analysis on the underlying mechanisms of baicalein against oral squamous cell carcinoma. J. Gene Med.25, e3490. 10.1002/jgm.3490
72
TasakiY.SugiyamaY.HamamotoS.NaikiT.UemuraT.YokotaK.et al (2023). Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: a retrospective multidisciplinary study. Cancer Med.12, 21666–21679. 10.1002/cam4.6724
73
TorresL. A. T.SilvaG.AlvesJ. S. F.UshidaT. R.PotenzaJ.GarciaC. B.et al (2024). FTY720 increases paclitaxel efficacy in cisplatin-resistant oral squamous cell carcinoma. J. Oral Pathol. Med.53, 42–52. 10.1111/jop.13498
74
TrocchianesiS.PoA.CitarellaA.SpinelloZ.RughettiA.BesharatZ. M.et al (2023). Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: aberrant activation of the HH-Gli signaling pathway in acquired resistance. Biomed. Pharmacother.164, 114995. 10.1016/j.biopha.2023.114995
75
TumbanE. (2019). A current update on human papillomavirus-associated head and neck cancers. Viruses11, 922. 10.3390/v11100922
76
VermorkenJ. B.GuigayJ.MesiaR.TrigoJ. M.KeilholzU.KerberA.et al (2011). Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br. J. Cancer104, 1691–1696. 10.1038/bjc.2011.152
77
von Bohlen Und HalbachO. (2011). How to judge a book by its cover? How useful are bibliometric indices for the evaluation of “scientific quality” or “scientific productivity”. Ann. Anat.193, 191–196. 10.1016/j.aanat.2011.03.011
78
WuZ.ChengK.ShenZ.LuY.WangH.WangG.et al (2022). Mapping knowledge landscapes and emerging trends of sonodynamic therapy: a bibliometric and visualized study. Front. Pharmacol.13, 1048211. 10.3389/fphar.2022.1048211
79
XiaoL.HuZ.-Y.DongX.TanZ.LiW.TangM.et al (2014). Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy. Oncogene33, 4568–4578. 10.1038/onc.2014.32
80
XingM.AlzahraniA. S.CarsonK. A.ShongY. K.KimT. Y.ViolaD.et al (2015). Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J. Clin. Oncol.33, 42–50. 10.1200/JCO.2014.56.8253
81
XueL.YangK.FangM.MaX.ZouW.DingM.et al (2023). Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). J. Clin. Oncol.41, 6037. 10.1200/JCO.2023.41.16_suppl.6037
82
YangC.-Y.HsiehC.-C.LinC.-K.LinC.-S.PengB.LinG.-J.et al (2017). Danshen extract circumvents drug resistance and represses cell growth in human oral cancer cells. BMC Complement. Altern. Med.17, 555. 10.1186/s12906-017-2063-y
83
YatskoV. A. (2012). The interpretation of Bradford’s law in terms of geometric progression. Autom. Doc. Math. Ling.46, 112–117. 10.3103/S0005105512020094
84
YuanL.JiaG.-D.LvX.-F.XieS.-Y.GuoS.-S.LinD.-F.et al (2023). Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial. Nat. Commun.14, 4893. 10.1038/s41467-023-40402-x
85
ZhangL.YaoQ.HuJ.QiuB.XiaoY.ZhangQ.et al (2024). Hotspots and trends of microglia in Alzheimer’s disease: a bibliometric analysis during 2000-2022. Eur. J. Med. Res.29, 75. 10.1186/s40001-023-01602-9
86
ZhangW.LiuT.LiX.LiT.MaX.ZhaoD.et al (2023). Identification of novel immune-related molecular subtypes and a prognosis model to predict thyroid cancer prognosis and drug resistance. Front. Pharmacol.14, 1130399. 10.3389/fphar.2023.1130399
Summary
Keywords
head and neck cancer, drug resistance, bibliometric analysis, research frontiers, data visualization
Citation
Han Q, Shi J, Liu J, Fu Y, Li Z, Guo H, Guan X, Xue X, Liu H, Zhao L and Zhang C (2024) Decoding the research landscape of drug resistance and therapeutic approaches in head and neck cancer: a bibliometric analysis from 2000 to 2023. Front. Pharmacol. 15:1375110. doi: 10.3389/fphar.2024.1375110
Received
23 January 2024
Accepted
25 March 2024
Published
05 April 2024
Volume
15 - 2024
Edited by
Ana Sofia Fernandes, Universidade Lusófona Research Center for Biosciences and Health Technologies, Portugal
Reviewed by
Olesya A. Kharenko, Syantra Inc., Canada
Harim Tavares Dos Santos, University of Missouri, United States
Updates
Copyright
© 2024 Han, Shi, Liu, Fu, Li, Guo, Guan, Xue, Liu, Zhao and Zhang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chunming Zhang, zcmsxmu@sxent.org; Qi Han, hanqi798@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.